Ozempic cardiovascular protection: FDA-approved to reduce heart attack, stroke, and CV death in T2D with heart disease. SUSTAIN 6: 26% reduction. STEP-HFpEF evidence for heart failure.
Ozempic program | Nepal treatment guide | FAQs | What is Ozempic? | Dosage | Who should avoid | Drug interactions | Monitoring | Results | Vs Wegovy vs Mounjaro | Diet & exercise | Price in Nepal | Stree Clinic | Lead Doctor | Weight loss | Diabetes care | Side effects | Success stories | Editorial policy | How to get Ozempic | Results timeline | Meal plan | Injection guide | Storage & cold chain | Myths vs facts | नेपालीमा | Conditions treated | Clinical trials | BMI eligibility | BMI calculator | Without diabetes | Fake semaglutide warning | Ozempic & alcohol | Vs Saxenda | PCOS | Fatty liver | Kidney disease | Prediabetes | Alternatives | Ozempic face | Hair loss | Stopping Ozempic | For men | For women | Not losing weight | Semaglutide in Nepal | GLP-1 treatment | Find a doctor | Availability | Medical weight loss | Obesity treatment | Diabetes doctor | Eligibility | Insulin resistance | Wegovy in Nepal | Mounjaro in Nepal | Rybelsus in Nepal | Areas served | Find a specialist | Weight loss medication | Book consultation | Ozempic vs keto | Vs low-carb | Vs calorie deficit | Vs exercise | Vs diet & exercise | Vs intermittent fasting | Vs fasting | Vs natural weight loss | Vs lifestyle changes | Vs medical weight mgmt | Vs dietitian-guided | Vs bariatric surgery | Request assessment
Yes — Ozempic is FDA-approved to reduce major cardiovascular events (heart attack, stroke, cardiovascular death) in type 2 diabetes patients with established cardiovascular disease. The SUSTAIN 6 trial showed a 26% reduction in these events.
SUSTAIN 6 showed semaglutide reduced the combined risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 26% in high-risk type 2 diabetes patients — a landmark cardiovascular protection result.
In obesity-related heart failure with preserved ejection fraction (HFpEF), the STEP-HFpEF trial showed semaglutide significantly improved symptoms, walking distance, and weight. This is an evidence-backed use in that specific patient group.
Multiple mechanisms: better blood sugar, weight loss, blood pressure improvement, reduced inflammation, and likely direct effects on blood vessels. The combined benefit reduces the cardiovascular events that kill diabetic patients.
Cardiovascular disease is a reason doctors often prefer GLP-1 agents — the evidence favors protection. Your specific heart history, medicines, and risk profile are reviewed before prescribing.
Browse all pages